Parallel Advisors, LLC Viridian Therapeutics, Inc.\De Transaction History
Parallel Advisors, LLC
- $4.34 Billion
- Q4 2024
A detailed history of Parallel Advisors, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Parallel Advisors, LLC holds 10 shares of VRDN stock, worth $167. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10
Previous 28
64.29%
Holding current value
$167
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
193Shares Held
78.5MCall Options Held
575KPut Options Held
441K-
Black Rock Inc. New York, NY4.77MShares$80.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$77.2 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$65.2 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$63 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$57.9 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $670M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...